Long-term Efficacy of Rilzabrutinib in Patients With Immune Thrombocytopenia by Madaline Spencer| Published on: Jan 19, 2026 +++++ +++++ +

CLINICAL PERSPECTIVES Long-term Efficacy of Rilzabrutinib in Patients With Immune Thrombocytopenia https://checkrare.com/long-term-efficacy-of-rilzabrutinib-in-patients-with-immune-thrombocytopenia/ David Kuter, MD, DPhil, Professor of Medicine at Harvard Medical School, Massachusetts General Hospital, discusses treatment with rilzabrutinib in patients with immune thrombocytopenia (ITP). Recent Data on Ravulizumab in Rare Hematologic Conditions https://checkrare.com/recent-data-on-raulizumab-in-rare-hematologic-disorders/ Anita Hill, MD, PhD, Global Medical Head for Hematology & Nephrology and Transplant at Alexion, AstraZeneca Rare Disease, discusses recent data on ravulizumab in rare hematologic conditions. Efficacy of Pozelimab + Cemdisiran To Treat Paroxysmal Nocturnal Hemoglobinuria https://checkrare.com/efficacy-of-pozelimab-cemdisiran-to-treat-paroxysmal-nocturnal-hemoglobinuria/ Jun Ho Jang, MD, PhD, Professor, Division of Hematology-Oncology at Samsung Medical Center, discusses results from an open-label extension study testing pozelimab plus cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH), who previously received the combination therapy or received ravulizumab. Treatment With Elritercept for Patients With Myelofibrosis https://checkrare.com/treatment-with-elritercept-for-patients-with-myelofibrosis/ Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF). Updated Phase 2 Results of Telquetamab + Teclistamab in Multiple Myeloma https://checkrare.com/updated-phase-2-results-of-telquetamab-teclistamab-in-multiple-myeloma/ Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM). Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma https://checkrare.com/results-from-the-cartitude-4-clinical-trial-in-multiple-myeloma/ Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM). Results of Part 1a of the OLYMPIA-3 Study of Odronextamab+Chemotherapy in Diffuse Large B Cell Lymphoma https://checkrare.com/results-of-part-1a-of-the-olympia-3-study-of-odronextamabchemotherapy-in-diffuse-large-b-cell-lymphoma/ Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL). Ibr+Ven Combination Therapy Versus Clb+Obi Combination Therapy in Chronic Lymphocytic Leukemia https://checkrare.com/ibrven-combination-therapy-versus-clbobi-combination-therapy-in-chronic-lymphocytic-leukemia/ Paolo Ghia, MD, PhD, Professor of Medical Oncology at the Università Vita-Salute San Raffaele in Milan, Italy, discusses data comparing ibrutinib plus venetoclax combination therapy with chlorambucil + obinutuzumab combination therapy in patients with chronic lymphocytic leukemia (CLL). Results from the LINKER-MM4 Clinical Trial in Multiple Myeloma https://checkrare.com/results-from-the-linker-mm4-clinical-trial-in-multiple-myeloma/ Robert Orlowski, MD, PhD, Professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses results from the LINKER-MM4 clinical trial testing Lynozyfic (linvoseltamab) to treat patients with newly diagnosed multiple myeloma (MM). The cAMeLot-2 Trial Testing Bleximenib Combination Therapy for Acute Myeloid Leukemia https://checkrare.com/the-camelot-2-trial-testing-bleximenib-combination-therapy-for-acute-myeloid-leukemia/ Elias Jabbour, MD, MD Anderson Cancer Center at the University of Texas, discusses the cAMeLot-2 study design of bleximenib combination therapy for patients with acute myeloid leukemia (AML). Phase 3 Data of Vonvendi for the Treatment of Von Willebrand Disease https://checkrare.com/phase-3-data-of-vonvendi-for-the-treatment-of-von-willebrand-disease/ Shayla Bergmann, MD, Pediatric Hematologist/Oncologist at the Medical University of South Carolina, discusses phase 3 data of Vonvendi for the treatment of Von Willebrand disease (VWD).